PREVALENZA E DISTRIBUZIONE IN LIGURIA

 

gaslini

CENTRO REGIONALE DI RIFERIMENTO PER LE MALATTIE EMORRAGICHE E L’INDIVIDUAZIONE DEL RISCHIO TROMBOTICO EREDITARIO

 

ISTITUTO GIANNINA GASLINI GENOVA

 

 

 

 

A.C. MOLINARI  2013    

 

 

 

PREVALENZA E DISTRIBUZIONE DELLE MALATTIE EMORRAGICHE CONGENITE IN LIGURIA

 

I pazienti con Malattie Emorragiche Congenite residenti in Liguria registrati e regolarmente seguiti presso il Centro Regionale di Riferimento per le Malattie Emorragiche (di seguito indicato semplicemente ‘Centro’) sono 277. Tra questi, sono noti 104 casi di emofilia A, 37 di emofilia B e 81 di malattia di von Willebrand (Tabella 1). 163 pazienti (60%) risiedono nella ASL 3; 175 ricevono regolarmente (in genere ogni 6-12 mesi) il piano terapeutico, elaborrato dal personale medico dal Centro previa valutazione clinica e dello stile di vita.

TABELLA 1: DISTRIBUZIONE DEI COAGULOPATICI CONGENITI IN LIGURIA1

PROVINCE

 

 

GE

SV

IM

SP

TOTALI

PATOLOGIA

13

1

3

1

18

EMOFILIA A GRAVE

7

1

3

1

12

EMOFILIA A MODERATA

64

5

5

0

74

EMOFILIA A LIEVE

3

4

2

1

10

EMOFILIA B GRAVE

3

1

0

0

4

EMOFILIA B MODERATA

19

2

1

1

23

EMOFILIA B LIEVE

3

1

0

0

4

VWD TIPO 3

21

5

0

2

28

VWD TIPO2

40

5

12

2

59

VWD TIPO 1

31

6

8

0

45

COAGULOPATIE RARE E PIASTRINOPATIE

204

31

34

8

277

TOTALE

 

 

 

 

 

 

Fascie di età:

 

 

 

 

>18 a

12 – 18 a

< 12 a

 

 

 

201

29

47

 

 

 

 

 

 

 Bibliografia

 

  • Associazione Italiana Centri Emofilia (AICE). Linee Guida per la terapia sostitutiva dell’emofilia e dei difetti ereditari della coagulazione

 

http://www.aiceonline.it/documenti%5CLineeGuida%5Citalia_Coagulopatie.pdf

 

  • Associazione Italiana Centri Emofilia (AICE). Dalla diagnosi di portatrice di emofilia alla diagnosi prenatale A cura di Peyvandi F, Tagliabue L, Menegatti M, et al. http://www.aiceonline.it/documenti/genetica/diagnosiportatrice.pdf

  • Associazione Italiana Centri Emofilia (AICE). LINEE GUIDA PER LA DIAGNOSI ED IL TRATTAMENTO DI PAZIENTI CON INIBITORI DEI FATTORI PLASMATICI DELLA COAGULAZIONE http://www.aiceonline.it/documenti%5CLineeGuida%5CAICE_guida_inib_2004_finale.pdf

  • Berntorp E, et al. Modern treatment of haemophilia. Bull World Health Organ 1995;73:691-701.

  • Bray GL, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994;83:2428-35.

  • Bullinger M, VON MS. Quality of life in children and families with bleeding disorders. J.Pediatr.Hematol.Oncol. 2003 Dec;25 Suppl 1:S64-S67.

  • Colvin BT, et al. European principles of haemophilia care. Haemophilia 2008;14:361-74.

  • Darby SC, et al. Mortality from liver cancer and liver disease inhaemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre DirectorsOrganisation. Lancet1997;350:1425-31.

  • Darby SC, et al.The impact of HIV on mortality rates in the complete UK haemophilia population. AIDS2004;20:525-33.

  • Di Paolantonio T, et al. Low risk of transmission of the human immunodeficiency virus by a solvent-detergent-treated commercial factor VIII concentrate. J Med Virol 1992;36:71-4.

  • Ehrenforth S, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992;339:594-8.

  • Evatt BL, et al. Comprehensive care for haemophilia around the world. Haemophilia2004;10:9-13.

  • Farrugia A. Guide for the assessment of clotting factor concentrates for the treatment of hemophilia. World Federation of Hemophilia, 2003.

  • Ghirardini A, et al. Epidemiology of hemophilia and of HIV infection in Italy. GICC. Gruppo Italiano Coagulopatie Congenite. J Clin Epidemiol1994;47:1297-306.

  • Iorio A, et al. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia 2008;14:444-53.

  • Kasper CK, et al. Registry of clotting factor concentrates, fifth edition. World Federation of Hemophilia, 2004.

  • Kitchen S, et al. Diagnosis of hemophilia and other bleeding disorders: A laboratory manual. World Federation of Hemophilia, 2000.

  • Lusher JM, et al. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. N Engl J Med 1993;328:453-9.

  • Manco-Johnson MJ, Riske B, Kasper CK. Advances in care of children with hemophilia. Semin.Thromb.Hemost. 2003 Dec;29(6):585-94.

  • Manco-Johnson MJ, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N.Engl.J.Med 2007 Aug 9;357(6):535-44.

  • Mannucci PM, Colombo M. Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. International Society for Thrombosis and Haemostasis. Thromb Haemost 1989;61:532-4.

  • Mannucci PM, et al. 1-Deamino-8-D-Arginine vasopressin: A new pharmacological approach to the management of haemophilia and von Willebrand's disease. Lancet 1977;1:869-72.

  • Mannucci PM, et al. Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group. Ann Intern Med 1990;113:27-32.

  • Mannucci PM, et al. Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator Group. Transfusion 1992;32:134-8.

  • Mannucci PM, et al. The hemophilias – from royal genes to gene therapy. N Engl J Med2001;344:1773-9.

  • Medical and Scientific Advisory Committee. Recommendation regarding the use of recombinant factor VIII in the treatment of haemophilia A. National Hemophilia Foundation: New York, 1996.

  • National Hemophilia Foundation. Standards and criteria for the care of persons with congenital bleeding disorders, 2002.

  • Ross C, et al. Athletic participation in severe hemophilia: bleeding and joint outcomes in children on prophylaxis. Pediatrics 2009 Nov;124(5):1267-72

  • Santagostino E, et al. Guidelines for replacement therapy for hemophilia and inherited coagulation disorders in Italy. Hemophilia 2000;6:1-10.

  • Santagostino E, et al. State of care for hemophilia in pediatric patients. Paediatr.Drugs 2002;4(3):149-57.

  • Scharrer I. The need for highly purified products to treat haemophilia B. Acta Haematologica 1995;94:2-7.

  • Schimpf K, et al. Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand’s disease with pasteurized factor VIII concentrate. N Engl J Med 1989;321:1148-52.

  • Street AM, et al. Management of carriers and babies with haemophilia. Haemophilia. 2008 Jul;14 Suppl 3:181-7.
    Tagliaferri A, et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008;14:945-51.

  • United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO). Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003;9:1-23.

  • White GC et al.Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.Thromb Haemost 2001;85:560.

  • World Federation of Hemophilia. Guidelines for the management of Hemophilia, 2005. http://www.ehc.eu/fileadmin/dokumente/Gudelines_Mng_Hemophilia.pdf

 

1 Aggiornata a giugno 2012

 

INDIETRO